enVVeno Medical Reports Positive VenoValve Pivotal Trial Data; 97% of Patients Show Clinical Improvement at Six Months

enVVeno Medical Corp

97% of VenoValve study patients showed clinical improvement at six months measured by revised Venous Clinical Severity Score (rVCSS).
74% of patients achieved clinically meaningful benefit (rVCSS improvement of 3 or more points).
Average rVCSS improvement per patient was 8 points, over 2.5 times the threshold for clinically meaningful benefit.
Company on track to file VenoValve FDA approval application (PMA) in Q4 2024.
Data presented at 2024 American Venous Forum Annual Meeting in Tampa, Florida on March 6, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.